DE69018990T2 - Stabile interleukine enthaltende impfstoffzusammensetzungen. - Google Patents

Stabile interleukine enthaltende impfstoffzusammensetzungen.

Info

Publication number
DE69018990T2
DE69018990T2 DE69018990T DE69018990T DE69018990T2 DE 69018990 T2 DE69018990 T2 DE 69018990T2 DE 69018990 T DE69018990 T DE 69018990T DE 69018990 T DE69018990 T DE 69018990T DE 69018990 T2 DE69018990 T2 DE 69018990T2
Authority
DE
Germany
Prior art keywords
vaccine compositions
interleukine
stable
compositions containing
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69018990T
Other languages
English (en)
Other versions
DE69018990D1 (de
Inventor
Subramonia Pillai
Garvin Bixler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Praxis Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biologics Inc filed Critical Praxis Biologics Inc
Application granted granted Critical
Publication of DE69018990D1 publication Critical patent/DE69018990D1/de
Publication of DE69018990T2 publication Critical patent/DE69018990T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69018990T 1989-07-14 1990-07-16 Stabile interleukine enthaltende impfstoffzusammensetzungen. Expired - Fee Related DE69018990T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14
PCT/US1990/003982 WO1991001143A1 (en) 1989-07-14 1990-07-16 Stable vaccine compositions containing interleukins

Publications (2)

Publication Number Publication Date
DE69018990D1 DE69018990D1 (de) 1995-06-01
DE69018990T2 true DE69018990T2 (de) 1995-12-14

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69018990T Expired - Fee Related DE69018990T2 (de) 1989-07-14 1990-07-16 Stabile interleukine enthaltende impfstoffzusammensetzungen.

Country Status (12)

Country Link
EP (1) EP0482076B1 (de)
JP (2) JP3485184B2 (de)
KR (1) KR0177179B1 (de)
AT (1) ATE121629T1 (de)
AU (1) AU648509B2 (de)
CA (1) CA2063587C (de)
DE (1) DE69018990T2 (de)
DK (1) DK0482076T3 (de)
ES (1) ES2075900T3 (de)
FI (1) FI104233B1 (de)
NO (1) NO301577B1 (de)
WO (1) WO1991001143A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
DE69032484D1 (de) * 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
EP0563254B1 (de) * 1990-12-19 1995-11-08 Schering Corporation Anwendung von il-4 zur steigerung der immunantwort auf immunogene in impfstoffen
EP0584212A4 (de) * 1991-05-13 1994-11-30 Univ California Liposomale polysaccharidimpfstoffe.
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP3982588B2 (ja) * 1992-08-10 2007-09-26 アメリカ合衆国 インターロイキン−４刺激ｔリンパ球細胞死
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
AU3541495A (en) * 1994-09-01 1996-03-22 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
EP1649868A1 (de) * 1996-05-31 2006-04-26 National University of Ireland, Maynooth IL-12 als Adjuvans für Bordetella pertussis Impfstoffe
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE60040740D1 (de) 1999-12-03 2008-12-18 Celltech Chiroscience Ltd VERWENDUNG OF INTERLEUkIN-1 MUTEIN ALS IMPFSTOFFADJUVANS
SG10201504917PA (en) 2005-07-11 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
WO2007039583A1 (en) * 2005-09-30 2007-04-12 Lipoxen Technologies Limited Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant
BRPI0713426A2 (pt) 2006-06-14 2012-10-09 Macrogenics Inc métodos de tratar, diminuir a progressão, ou melhorar um ou mais sintomas de um distúrbio, e de prevenir ou retardar o inìcio de um distúrbio
EP2129394B1 (de) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Impfstoffzusammensetzung gegen papillomavirus
CA2890258C (en) * 2012-11-02 2020-10-20 Cytuvax Composition comprising cytokine macro-aggregates
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
JP2022507606A (ja) 2018-11-16 2022-01-18 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
KR20220150274A (ko) 2020-01-13 2022-11-10 네오이뮨텍, 인코퍼레이티드 Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
US20230398184A1 (en) 2020-10-26 2023-12-14 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
US20240115675A1 (en) 2020-11-05 2024-04-11 Neoimmunetech, Inc. Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
AU648509B2 (en) 1994-04-28
NO301577B1 (no) 1997-11-17
KR0177179B1 (ko) 1999-03-20
NO920161L (no) 1992-03-05
ATE121629T1 (de) 1995-05-15
AU6050090A (en) 1991-02-22
FI104233B (fi) 1999-12-15
FI104233B1 (fi) 1999-12-15
EP0482076B1 (de) 1995-04-26
FI920132A0 (fi) 1992-01-13
ES2075900T3 (es) 1995-10-16
CA2063587C (en) 2005-08-30
KR920703103A (ko) 1992-12-17
EP0482076A1 (de) 1992-04-29
JPH04506663A (ja) 1992-11-19
DK0482076T3 (da) 1995-07-17
JP3485184B2 (ja) 2004-01-13
DE69018990D1 (de) 1995-06-01
CA2063587A1 (en) 1991-01-15
JP2004002463A (ja) 2004-01-08
NO920161D0 (no) 1992-01-13
WO1991001143A1 (en) 1991-02-07

Similar Documents

Publication Publication Date Title
DE69018990D1 (de) Stabile interleukine enthaltende impfstoffzusammensetzungen.
FI945483A (fi) Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
MX9203294A (es) Factor de estimulacion de aniquilador natural.
IT8322155A0 (it) Procedimento per immobilizzare materie biologiche e composto di materie biologiche adsorbite in vermiculite.
MX9803290A (es) Composiciones de la vacuna influenza.
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
GB8403921D0 (en) Preparation of lyophilized adsorbed polyvalent vaccines
YU48397B (sh) Izolat trichoderma harzianum t-39 fungicidalna jedinjenja koja sadrže pomenuti izolat i upotreba protiv b. cinerea i s. sclerotiorum.
NO176231C (no) Zn-modifisert silika og anvendelse av denne
DK0732936T3 (da) Adjuvans til antigener, fremgangsmåde til fremstilling og anvendelse
ATE61937T1 (de) Antigenische zubereitungen und isolierung von solchen zubereitungen.
SE8404707D0 (sv) Komposition innehallande pyridinlosligt extrakt och raffinerat detoxifierat endotoxin samt anvendning derav
AU1813701A (en) Interleukin-1 muteins useful as vaccine adjuvants
ATE275421T1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
DK0884329T3 (da) Anti-idiotypisk antistof, som inducerer en immunreaktion mod et glycosphingolipid, samt anvendelse deraf
AU4831401A (en) TH1 inducing natural adjuvant for heterologous antigens
DK504389D0 (da) Adjuveret antigenoploesning, dens fremstilling samt zink- eller jernhydroxidgel til anvendelse derved
ES2088431T3 (es) Preparacion biologica y su utilizacion.
ES2056378T3 (es) Procedimiento de extraccion.
GB2227936A (en) Vaccine against brucella abortus
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
SE8404090D0 (sv) Raffinerat detoxifierat endotoxin
GR1000881B (el) Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
KR890700355A (ko) 단백질-함유 항원의 부분양이온화와 면역화 및 탈감작법.
ATE177010T1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AMERICAN CYANAMID CO., PORTLAND, ME., US

8327 Change in the person/name/address of the patent owner

Owner name: WYETH HOLDINGS CORP., MADISON, N.J., US

8339 Ceased/non-payment of the annual fee